Related Experiment Video
Updated: Oct 14, 2025
Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device
Published on: May 2, 2025
Clinical trial challenges, design considerations, and outcome measures in rare CNS tumors
Terri S Armstrong1, Mark R Gilbert1
1Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Abstract:
Clinical research for patients with rare cancers has been very challenging. First and foremost, patient accrual to clinical trials typically requires a network, cooperative group, or even international collaboration in order to achieve the necessary numbers of patients to adequately evaluate a new treatment or intervention. Similar limitations in preclinical models and in the understanding the natural history of the disease or pertinent prognostic factors further impede the development of hypothesis-based, appropriately powered clinical trials. However, despite these challenges, several studies in rare cancers, including ependymoma and subependymal giant cell astrocytoma, have helped to establish new treatment regimens. Importantly, in these seminal trials, patient outcomes measures were critical in describing the clinical benefit derived from the therapy, underscoring the need to incorporate these measures in future trials. While obstacles still remain, novel and creative approaches to clinical trial designs have been developed that can be used to study new treatments for patients with rare cancers, thereby addressing a significant unmet need.
Insights
Conducting clinical trials for rare cancers is difficult due to low patient numbers and limited research models. Novel trial designs and outcome measures are crucial for developing effective treatments for rare cancer patients.
Area of Science:
- Oncology
- Clinical Research
Background:
- Clinical research for rare cancers faces significant challenges, including difficulties in patient accrual for clinical trials.
- Limited preclinical models and incomplete understanding of disease natural history hinder the development of well-powered clinical trials.
Purpose of the Study:
- To review the challenges and successes in rare cancer clinical research.
- To highlight the importance of patient outcomes measures in evaluating new treatments for rare cancers.
- To discuss novel approaches for rare cancer clinical trial design.
Main Methods:
- Review of existing literature on rare cancer clinical trials.
- Analysis of successful treatment regimens established in rare cancer studies.
- Examination of patient outcomes measures in rare cancer research.
Main Results:
- Despite challenges, studies in rare cancers like ependymoma have led to new treatment regimens.
- Patient-reported outcomes were critical in demonstrating clinical benefit in seminal rare cancer trials.
- Novel clinical trial designs are emerging to address unmet needs in rare cancer research.
Conclusions:
- Effective rare cancer clinical research requires collaborative networks and innovative trial designs.
- Incorporating robust patient outcomes measures is essential for future rare cancer studies.
- Creative approaches are vital to advance treatment development for rare cancer patients.
More Related Videos
05:22Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice
Published on: February 24, 2023
11:09Establishing Intracranial Brain Tumor Xenografts With Subsequent Analysis of Tumor Growth and Response to Therapy using Bioluminescence Imaging
Published on: July 13, 2010
Related Concept Videos
01:11Clinical Trials: Overview
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
02:56Treatment Resistant Cancers
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...